Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial

Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The ClinicalTrials.gov page displays the record for the terminated Phase 1 multiple myeloma study, including its eligibility criteria, interventions, outcomes, and study documents, instead of a 403 error.
    Difference
    67%
    Check dated 2026-11-08T12:35:53.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0 while the study page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T13:30:18.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    A banner was added announcing an NIH website transition and updates about terminology for artificial intelligence. The study record remains unavailable behind a 403 error.
    Difference
    1%
    Check dated 2026-10-25T13:11:07.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T14:10:07.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.0 to v3.7.1; the study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T13:31:22.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    A 403 Forbidden error page was added, displaying a minimal header and a Home link, indicating restricted access to the study record rather than a content update.
    Difference
    0.5%
    Check dated 2026-09-27T18:18:29.000Z thumbnail image

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.